Compare Incyte Corporation (INCY) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs The Coca-Cola Co K — how do they compare? Incyte Corporation trades at $112.75 (market cap $22.85B), while The Coca-Cola Co K trades at $87.38 (market cap $377.63B). The key difference: The Coca-Cola Co K is far larger — about 16.5× Incyte Corporation's market cap, and The Coca-Cola Co K pays a 2.42% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and The Coca-Cola Co K for 154 Days on average.
| INCY | KO | |
|---|---|---|
Market Cap | $22.85B | $377.63B |
Volume | 1,927,029 | 14,894,568 |
Sector | Health | Consumer Staples |
52-Week High | $129.93 | $91.99 |
52-Week Low | $83.80 | $66.37 |
Typical Hold Time | 33 Days | 154 Days |
Enterprise Value | $18.35B | $404.81B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical outlook despite mixed moving average signals. The company shows strong fundamentals with $5.14B revenue, 27.71% net margin, and robust cash flow of $1.41B. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI position the company for growth, with analysts projecting $5.8B revenue and $1.6B net income for 2026.
The investment case centers on Incyte's successful diversification strategy and strong profitability metrics, though investors face risks from JAKAFI patent expiration in 2029 and near-term earnings volatility. With 52% analyst buy ratings and a $132.43 consensus price target representing 17% upside, the stock offers growth potential but requires monitoring of pipeline execution.
Coca-Cola (KO) trades at $85.82, down 0.41% on the day, with a bearish technical signal despite strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.97 exceeding expectations. KO maintains robust profitability with 61.89% gross margins and 28.56% net income margins, supported by steady revenue growth and a dominant market position.
The stock presents a compelling dividend opportunity with 64 consecutive years of increases, though technical indicators suggest near-term pressure. Analyst consensus remains bullish with a $95.75 price target, representing 11.6% upside potential. Key risks include regional demand divergence and high valuation multiples that may limit short-term appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
